Scilex (SCLX) Competitors

$6.29 -0.21 (-3.23%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$6.30 +0.01 (+0.24%)

As of 05/15/2026 05:45 PM Eastern

SCLX vs. MNPR, CMPX, IMRX, EOLS, and BCYC

Should you buy Scilex stock or one of its competitors? MarketBeat compares Scilex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scilex include Monopar Therapeutics (MNPR), Compass Therapeutics (CMPX), Immuneering (IMRX), Evolus (EOLS), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry.

How does Scilex compare to Monopar Therapeutics?

Scilex (NASDAQ:SCLX) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Scilex has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Monopar Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,185.78%. Scilex's return on equity of 0.00% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,185.78%	N/A	-178.57%
Monopar Therapeutics	N/A	-13.56%	-13.27%

Monopar Therapeutics has lower revenue, but higher earnings than Scilex. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	1.77	-$358.73M	-$36.45	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

69.7% of Scilex shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 4.1% of Scilex shares are held by company insiders. Comparatively, 20.5% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Monopar Therapeutics had 2 more articles in the media than Scilex. MarketBeat recorded 5 mentions for Monopar Therapeutics and 3 mentions for Scilex. Monopar Therapeutics' average media sentiment score of 1.58 beat Scilex's score of 1.13 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scilex	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monopar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Monopar Therapeutics has a consensus target price of $107.00, suggesting a potential upside of 80.53%. Given Monopar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Monopar Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Monopar Therapeutics beats Scilex on 11 of the 16 factors compared between the two stocks.

How does Scilex compare to Compass Therapeutics?

Scilex (NASDAQ:SCLX) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

In the previous week, Compass Therapeutics had 2 more articles in the media than Scilex. MarketBeat recorded 5 mentions for Compass Therapeutics and 3 mentions for Scilex. Scilex's average media sentiment score of 1.13 beat Compass Therapeutics' score of 0.38 indicating that Scilex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scilex	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Compass Therapeutics has lower revenue, but higher earnings than Scilex. Compass Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	1.77	-$358.73M	-$36.45	N/A
Compass Therapeutics	$850K	394.08	-$66.49M	-$0.41	N/A

Compass Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,185.78%. Scilex's return on equity of 0.00% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,185.78%	N/A	-178.57%
Compass Therapeutics	N/A	-39.75%	-35.29%

Scilex has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

69.7% of Scilex shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 4.1% of Scilex shares are owned by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Compass Therapeutics has a consensus price target of $13.60, indicating a potential upside of 631.18%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Compass Therapeutics beats Scilex on 11 of the 17 factors compared between the two stocks.

How does Scilex compare to Immuneering?

Scilex (NASDAQ:SCLX) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

69.7% of Scilex shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 4.1% of Scilex shares are held by insiders. Comparatively, 22.9% of Immuneering shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Immuneering had 1 more articles in the media than Scilex. MarketBeat recorded 4 mentions for Immuneering and 3 mentions for Scilex. Immuneering's average media sentiment score of 1.22 beat Scilex's score of 1.13 indicating that Immuneering is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scilex	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immuneering has a net margin of 0.00% compared to Scilex's net margin of -1,185.78%. Scilex's return on equity of 0.00% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,185.78%	N/A	-178.57%
Immuneering	N/A	-43.33%	-39.75%

Immuneering has a consensus price target of $16.50, indicating a potential upside of 219.77%. Given Immuneering's stronger consensus rating and higher probable upside, analysts plainly believe Immuneering is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Scilex has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

Immuneering has lower revenue, but higher earnings than Scilex. Immuneering is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	1.77	-$358.73M	-$36.45	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.38	N/A

Summary

Immuneering beats Scilex on 11 of the 16 factors compared between the two stocks.

How does Scilex compare to Evolus?

Scilex (NASDAQ:SCLX) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

In the previous week, Scilex and Scilex both had 3 articles in the media. Evolus' average media sentiment score of 1.67 beat Scilex's score of 1.13 indicating that Evolus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scilex	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evolus	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Evolus has a consensus price target of $16.00, indicating a potential upside of 146.15%. Given Evolus' stronger consensus rating and higher possible upside, analysts clearly believe Evolus is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Scilex has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Evolus has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

Evolus has a net margin of -14.39% compared to Scilex's net margin of -1,185.78%.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,185.78%	N/A	-178.57%
Evolus	-14.39%	N/A	-19.03%

Evolus has higher revenue and earnings than Scilex. Evolus is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	1.77	-$358.73M	-$36.45	N/A
Evolus	$301.79M	1.42	-$51.64M	-$0.67	N/A

69.7% of Scilex shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 4.1% of Scilex shares are held by insiders. Comparatively, 5.0% of Evolus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Evolus beats Scilex on 11 of the 14 factors compared between the two stocks.

How does Scilex compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Bicycle Therapeutics presently has a consensus price target of $14.00, suggesting a potential upside of 214.61%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Bicycle Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bicycle Therapeutics has a net margin of -344.95% compared to Scilex's net margin of -1,185.78%. Scilex's return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Scilex	-1,185.78%	N/A	-178.57%

86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 22.9% of Bicycle Therapeutics shares are held by insiders. Comparatively, 4.1% of Scilex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bicycle Therapeutics has higher revenue and earnings than Scilex. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$63.50M	4.89	-$218.96M	-$3.15	N/A
Scilex	$30.25M	1.77	-$358.73M	-$36.45	N/A

In the previous week, Scilex had 2 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 3 mentions for Scilex and 1 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.41 beat Scilex's score of 1.13 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Bicycle Therapeutics	Positive
Scilex	Positive

Bicycle Therapeutics has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market. Comparatively, Scilex has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

Summary

Bicycle Therapeutics beats Scilex on 12 of the 16 factors compared between the two stocks.

Get Scilex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCLX vs. The Competition

Export

Metric	Scilex	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$53.41M	$3.31B	$6.37B	$12.30B
Dividend Yield	N/A	2.32%	2.80%	5.26%
P/E Ratio	-0.17	18.50	20.66	25.27
Price / Sales	1.77	183.64	531.43	62.37
Price / Cash	N/A	121.77	42.43	54.86
Price / Book	-0.25	6.63	9.87	6.90
Net Income	-$358.73M	$24.40M	$3.57B	$334.66M
7 Day Performance	-19.57%	4.14%	0.23%	0.12%
1 Month Performance	-8.84%	-4.80%	-2.54%	-0.18%
1 Year Performance	49.41%	62.87%	33.54%	30.62%

Scilex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCLX Scilex	0.6837 of 5 stars	$6.29 -3.2%	N/A	+49.4%	$53.41M	$30.25M	N/A	80	Positive News
MNPR Monopar Therapeutics	2.3886 of 5 stars	$54.64 +2.6%	$107.00 +95.8%	+59.5%	$356.36M	N/A	N/A	10	News Coverage Positive News Earnings Report Analyst Revision Gap Down
CMPX Compass Therapeutics	3.1492 of 5 stars	$1.94 -1.0%	$13.60 +601.0%	-11.4%	$352.97M	$850K	N/A	20	Gap Down
IMRX Immuneering	2.2942 of 5 stars	$5.39 +0.4%	$16.50 +206.1%	+258.3%	$347.42M	N/A	N/A	60	Earnings Report
EOLS Evolus	2.6128 of 5 stars	$5.58 +4.7%	$16.00 +186.7%	-33.0%	$346.77M	$297.18M	N/A	170	Analyst Upgrade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCLX) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scilex (SCLX) Competitors

SCLX vs. MNPR, CMPX, IMRX, EOLS, and BCYC

How does Scilex compare to Monopar Therapeutics?

Summary

How does Scilex compare to Compass Therapeutics?

Summary

How does Scilex compare to Immuneering?

Summary

How does Scilex compare to Evolus?

Summary

How does Scilex compare to Bicycle Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLX vs. The Competition

Scilex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scilex (SCLX) Competitors

SCLX vs. MNPR, CMPX, IMRX, EOLS, and BCYC

How does Scilex compare to Monopar Therapeutics?

Which has more risk & volatility, SCLX or MNPR?

Is SCLX or MNPR more profitable?

Which has better earnings & valuation, SCLX or MNPR?

Do insiders & institutionals believe in SCLX or MNPR?

Does the media refer more to SCLX or MNPR?

Do analysts prefer SCLX or MNPR?

Summary

How does Scilex compare to Compass Therapeutics?

Does the media favor SCLX or CMPX?

Which has higher valuation and earnings, SCLX or CMPX?

Is SCLX or CMPX more profitable?

Which has more volatility and risk, SCLX or CMPX?

Do insiders & institutionals have more ownership in SCLX or CMPX?

Do analysts recommend SCLX or CMPX?

Summary

How does Scilex compare to Immuneering?

Do insiders and institutionals believe in SCLX or IMRX?

Does the media prefer SCLX or IMRX?

Is SCLX or IMRX more profitable?

Do analysts rate SCLX or IMRX?

Which has more risk and volatility, SCLX or IMRX?

Which has better earnings and valuation, SCLX or IMRX?

Summary

How does Scilex compare to Evolus?

Does the media favor SCLX or EOLS?

Do analysts prefer SCLX or EOLS?

Which has more risk & volatility, SCLX or EOLS?

Is SCLX or EOLS more profitable?

Which has higher valuation and earnings, SCLX or EOLS?

Do institutionals and insiders hold more shares of SCLX or EOLS?

Summary

How does Scilex compare to Bicycle Therapeutics?

Do analysts prefer BCYC or SCLX?

Is BCYC or SCLX more profitable?

Do insiders and institutionals have more ownership in BCYC or SCLX?

Which has stronger earnings & valuation, BCYC or SCLX?

Does the media favor BCYC or SCLX?

Which has more volatility & risk, BCYC or SCLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLX vs. The Competition

Scilex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools